生物
数量性状位点
遗传学
特质
基因座(遗传学)
疾病
阿尔茨海默病
基因
医学
内科学
计算机科学
程序设计语言
作者
José V. Sánchez‐Mut,Holger Heyn,Bianca A. Silva,Lucie Dixsaut,Paula Garcia‐Esparcia,Enrique Vidal,Sergi Sayols,Liliane Glauser,Ana Monteagudo,Jordi Pérez‐Tur,Isidró Ferrer,David Monk,Bernard L. Schneider,Manel Esteller,Johannes Gräff
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2018-05-01
卷期号:24 (5): 598-603
被引量:111
标识
DOI:10.1038/s41591-018-0013-y
摘要
The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors 1 , the latter likely being mediated by epigenetic mechanisms 2 . In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology 3 , but a causal relationship remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations, which provide mechanistic insights for a particular risk gene but often lack the statistical power of GWAS 4 . Here, combining both approaches, we report a previously unidentified association of the peptidase M20-domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation and expression quantitative trait locus coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CCCTC-binding-factor-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults at symptomatic stages in the APP/PS1 mouse model of AD and in human patients with AD who are carriers of the non-risk haplotype. In line, genetically increasing or decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI